The B-cell maturation antigen (BCMA) has emerged as a promising target for multiple myeloma (MM) therapies, being preferentially expressed by mature B lymphocytes and deficient in HSCs and nonhematopoietic tissue [152]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.